Literature DB >> 21686626

Ocular phenylephrine 2.5% continues to be dangerous.

Nauman Ahmed1, Waleed Riad, Abdullah Altorpaq, Abdul Zahoor.   

Abstract

Phenylephrine 10% is used for pupillary dilatation and capillary decongestion. It had been advised to use a 2.5% concentration instead of 10% to guard against systemic reactions. Here, a case of severe systemic manifestation following conjuctival application of 2.5% phenylephrine is described.A healthy adult was admitted for pterygium excision under ophthalmic blockade. Vital signs remained normal until a sponge soaked with phenylephrine 2.5% was applied over the excised pterygium to control bleeding. The patient developed bradycardia (heart rate of 30 bpm) and hypotension (pressure 80/40 mmHg), so intravenous atropine was given. This was followed by tachycardia (heart rate of 150 bpm) and hypertension (pressure 240/130 mmHg) and ECG showed ischaemic changes. Treatment included propofol, labetalol, frusamide, morphine and dexamethasone. The next day, a 12-lead ECG showed no ischaemic changes and the myocardial infarction screen was negative. Fundus examination showed no sign of papilloedema. This report emphasises that phenylephrine 2.5% is still dangerous, with unpredictable response.

Entities:  

Year:  2009        PMID: 21686626      PMCID: PMC3029574          DOI: 10.1136/bcr.08.2008.0795

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  14 in total

1.  Comparison of the cardiovascular effects of 2.5% phenylephrine and 10% phenylephrine during ophthalmic surgery.

Authors:  R Malhotra; G Banerjee; W Brampton; N C Price
Journal:  Eye (Lond)       Date:  1998       Impact factor: 3.775

2.  Phenylephrine toxicity.

Authors:  M Macmillan; K Barker
Journal:  Eur J Anaesthesiol       Date:  2008-05       Impact factor: 4.330

3.  Prevention of hypotension after propofol for rapid sequence intubation.

Authors:  T Gin
Journal:  Can J Anaesth       Date:  1996-08       Impact factor: 5.063

4.  Possible cardiovascular effects secondary to topical ophthalmic 2.5% phenylephrine.

Authors:  F T Fraunfelder; S M Meyer
Journal:  Am J Ophthalmol       Date:  1985-03-15       Impact factor: 5.258

5.  Systemic effects of eye drops.

Authors:  A G Adler; G E McElwain; G J Merli; J H Martin
Journal:  Arch Intern Med       Date:  1982-12

6.  Adverse systemic effects from pledgets of topical ocular phenylephrine 10%.

Authors:  Frederick W Fraunfelder; Frederick T Fraunfelder; Bree Jensvold
Journal:  Am J Ophthalmol       Date:  2002-10       Impact factor: 5.258

7.  Intraoperative pulmonary oedema in a child following systemic absorption of phenylephrine eyedrops.

Authors:  F J Baldwin; A P Morley
Journal:  Br J Anaesth       Date:  2002-03       Impact factor: 9.166

8.  New York State guidelines on the topical use of phenylephrine in the operating room. The Phenylephrine Advisory Committee.

Authors:  S B Groudine; I Hollinger; J Jones; B A DeBouno
Journal:  Anesthesiology       Date:  2000-03       Impact factor: 7.892

Review 9.  Review: systemic absorption of topically applied ocular drugs in humans.

Authors:  L Salminen
Journal:  J Ocul Pharmacol       Date:  1990

10.  Reduction of phenylephrine drop size in infants achieves equal dilation with decreased systemic absorption.

Authors:  M G Lynch; R H Brown; S M Goode; R D Schoenwald; D S Chien
Journal:  Arch Ophthalmol       Date:  1987-10
View more
  1 in total

1.  Pupillary Dilation in Research: More than Meets the Eye.

Authors:  Jacob Szpernal; Jane A Bachman Groth; Niamh Wynne; Vesper Williams; Ryan Spellecy; Catherine Thuruthumaly; Joseph Carroll
Journal:  Curr Eye Res       Date:  2022-05-02       Impact factor: 2.555

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.